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A B S T R A C T
The Chinese Glioma Cooperative Group (CGCG) Guideline Panel for adult diffuse gliomas provided rec-
ommendations for diagnostic and therapeutic procedures. The Panel covered all ﬁelds of expertise in neuro-
oncology, i.e. neurosurgeons, neurologists, neuropathologists, neuroradiologists, radiation and medical
oncologists and clinical trial experts. The task made clearer and more transparent choices about out-
comes consideredmost relevant through searching the references consideredmost relevant and evaluating
their value. The scientiﬁc evidence of papers collected from the literature was evaluated and graded based
on the Oxford Centre for Evidence-based Medicine Levels of Evidence and recommendations were given
accordingly. The recommendations will provide a framework and assurance for the strategy of diagnos-
tic and therapeutic measures to reduce complications from unnecessary treatment and cost. The guideline
should serve as an application for all professionals involved in the management of patients with adult
diffuse glioma and also as a source of knowledge for insurance companies and other institutions in-
volved in the cost regulation of cancer care in China.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
There is currently no clear national consensus for the optimal
diagnosis and treatment of adult gliomas. This guideline devel-
oped is primarily an effort to assess the evidence for management
of adult gliomas in a manner that sets a benchmark for further
improvement, and to document the recommendations of the
Chinese Glioma Cooperative Group (CGCG) in patients with
gliomas. It covers WHO grade II/III astrocytomas, oligodendroglio-
mas, and oligoastrocytomas; and WHO grade IV glioblastomas.
The guideline includes diagnosis (including neuroimaging,
pathology and molecular information), general management strat-
egy and speciﬁc treatment plans for gliomas, supportive care and
response evaluation and follow-up. It has also been circulated to
CGCG members, including neurosurgeons, medical and radiation
oncologists, neuropathologists, neuroradiologists and epidemiolo-
gists for comments before the ﬁnal consensus document was drawn
up.
These recommendations provided are set forth for conscien-
tious use by the practicing physician who must take into account
all of the circumstances in the supervision of a given individual
illness. Furthermore, the recommendations could serve as a valu-
able source of information for multidisciplinary medical
professionals, patients, relatives, and oﬃcial health departments.
Epidemiology and survival
According to the multicenter cross-sectional study on brain
tumor (MCSBT) in China [1], age standardized prevalence of primary
brain tumor is 22.52 per million for all populations and gliomas
account for 31.1% in those aged 20–59 years. Diffuse gliomas are
diagnosed as astrocytomas, oligoastrocytomas and oligodendro-
gliomas of grades II and III and glioblastomas (GBM) of grade IV
based on the 2007 World Health Organization (WHO) CNS tumors
classiﬁcation [2]. Diffuse and anaplastic astrocytomas represent
about 25.2% of gliomas. Oligoastrocytic tumors and oligodendro-
gliomas, including anaplastic oligodendrogliomas, account for
about 18% of gliomas. And glioblastomas occupy about 30% of CNS
gliomas [3].
Based on the Chinese Glioma Genome Atlas (CGGA) statistics,
malignant gliomas have an unfavorable prognosis with median
overall survival times (OS) of 78.1 months for low-grade gliomas
(WHOGrade II), 37.6 months for anaplastic gliomas and 14.4months
for GBMs. For low-grade gliomas, the 6-month, 1-, 3-, and 5-year
OS rates were 99, 94, 79 and 67%, respectively; for anaplastic gliomas,
they were 88, 75, 51 and 36%, respectively; and for GBMs, they were
87, 61, 15 and 9%, respectively [4].
Diagnosis and pathology
Gliomas are diagnosed using morphological criteria according
to WHO classiﬁcation [2]. Diffuse astrocytoma cells histologically
represent stellate, spindle-shapedwith ﬁber like processes, or plump
with a large eosinophilic cytoplasmic mass. Anaplastic astrocyto-
mas showmoremalignant cytological features – cellularity, anaplasia
and mitoses. Glioblastoma arises most commonly de novo (primary
glioblastoma). Some glioblastomas arise by malignant transforma-
tion of lower-grade astrocytomas (secondary glioblastoma) [5].
Primary glioblastomas are more common in older patients and are
more aggressive. Microscopically, glioblastoma shows high cellu-
larity, cellular and nuclear anaplasia, mitoses, microvascular
proliferation, and necrosis. Oligodendroglioma cells, microscopi-
cally, are uniform and have round central nuclei with ﬁne chromatin
surrounded by a clear halo (unstained cytoplasm), which is an ar-
tifact of processing. Oligodendrogliomas are traversed by a delicate
capillary network and have a tendency to calcify, which is helpful
in radiological and histological diagnoses. Some oligodendroglio-
mas contain neoplastic astrocytes which are mixed with the
oligodendroglial cells or grow in adjacent but separate areas. Such
mixed tumors are called oligoastrocytomas. Oligodendrogliomas and
oligoastrocytomas can be classiﬁed as low-grade (WHO grade II) or
high grade/anaplastic (WHO grade III) based on cellularity, anapla-
sia, mitotic activity, microvascular proliferation, and necrosis.
Molecular biomarkers
IDH mutation
Mutations in the isocitrate dehydrogenase (IDH) gene primari-
ly locate at codon R132 in IDH1 and R172 in IDH2. IDH1/2mutations
are the earliest genetic alteration and mainly occur in WHO grade
II and III astrocytic and oligodendroglial tumors and in secondary
GBMs, which develop from lower grade astrocytomas [6]. IDH2 mu-
tations are less frequent compared with IDH1 mutations. However,
IDH 1/2 play the same role, catalyzing the oxidative carboxylation
of isocitrate to a-ketoglutarate, resulting in the reduction of NADP
to NADPH [7]. IDH1/2mutational status is of notable diagnostic value,
and particularly rare in primary glioblastoma [8]. IDH1/2 muta-
tions commonly indicate a favorable prognosis independent of WHO
grades [7,9,10].
Codeletion of chromosomal arms 1p and 19q
Combined loss of chromosomal arms 1p and 19q resulting from
an unbalanced t(1;19)(q10;p10) leads to loss of heterozygosity [11],
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associated with oligodendroglial histology and rarely found in other
tumors [12]. Patients with tumors lacking 1p and 19q have longer
median survival times and progression-free survival [13,14]. Most
oligodendrogliomas with 1p and 19q codeletion also carry muta-
tions in the CIC gene on chromosome 19q and the FUBP1 gene on
chromosome 1p [15–17].
MGMT promoter methylation and miR-181d
Methylation of O(6)-methylguanine-DNA methyl transferase
(MGMT) promoter, a prognostic and predictive factor [18,19], cor-
relates with beneﬁt from alkylating agent chemotherapy in patients
with IDH1 wild type malignant gliomas of WHO grades III/IV [20].
Besides epigenetic silencing,miR-181d also leads to decreasedmRNA
stability and/or reduced protein translation by binding to the 3′
untranslated region of MGMT transcripts, and predicts the surviv-
al and response of alkylating agent chemotherapy in glioblastoma
[21–23].
EGFRvIII
The EGFRvIII, a characteristic deletion exons 2–7 of the EGFR gene,
is expressed in approximately 20–30% of primary GBM, resulting
in constitutive and ligand-independent receptor activity and re-
garded as an important oncogenic mutation [24,25]. Long-term
survival might be worse in patients whose tumors carry this mu-
tation than in those who do not. As EGFRvIII is most common in
primary GBM and is not expressed on normal tissues, it is an ef-
fective target for immunotherapy [26].
ATRX mutations or loss
Mutations of alpha thalassemia/mental retardation syndrome
X-linked (ATRX) strongly correlated with its loss of expression, and
may predict better prognosis in astrocytic tumors with IDH muta-
tions [15,27]. ATRX mutation or loss of expression results in ALT and
genomic instability [28,29]. The protein encoded by ATRX plays mul-
tiple cellular roles, including chromatin remodeling at telomeres
[30,31]. Furthermore, loss of ATRX expression may deﬁne a sub-
group of astrocytic tumors with a more favorable prognosis [9,27].
TERT promoter mutation
Telomerase reverse transcriptase (TERT), which is essential in
maintaining telomere length and its activity, is pathologically in-
creased in gliomas. Recurrent mutations in the promoter region of
TERT most occurred in oligodendroglial tumors and primary glio-
blastoma, leading to TERT upregulation [32]. The prognostic value
of TERT promoter mutation remains controversial in IDH wild type
glioblastoma [33,34]. Combined analysis of 1p/19q codeletion, IDH
and TERT promoter mutational status may contribute to deﬁne prog-
nostic subgroups of gliomas [35–38].
Ki-67
Ki-67 is a nuclear protein expressed during the G1, S, G2 and M
phases of the cell cycle, and has been widely used as a stable marker
of cell proliferation in various types of human tumors, includingma-
lignant gliomas [39]. Ki-67 is an independent prognostic indicator,
associated with poor survival in gliomas regardless of WHO grades
[4,9].
Recent published studies [35,40–42] validated prior reports that
speciﬁc combinations of genetic alternations in IDH1/2, TERT, ATRX
and codeletion of 1p/19q have the ability to reclassify gliomas into
rational subsets, deﬁning a glioma’s biological and clinical behav-
iors more accurately than stratiﬁcations based solely on
histopathology. Lower grade gliomas (WHO grade II and III gliomas)
have an extremely high frequency of IDH1/2 mutation, which is ac-
companied either by 1p and 19q codeletion and a mutated TERT
promoter or by TP53 mutations with or without ATRX mutations.
Grade II or III astrocytomas mainly depicted the mutations in IDH1/
2, ATRX and TP53, while grade II and III oligodendrogliomas are
characterized by 1p/19q codeletion and themutations in IDH1/2 and
TERT promoter. Numerous evidence showed that oligoastrocytomas
(WHO grades II and III) may segregate into two groups, genetical-
ly matching oligodendroglioma on one and astrocytoma on the other
side based on the molecular information, for example, IDH1/2, 1p/
19q and ATRX, and so on [43,44]. Most lower grade gliomas without
an IDH mutation were molecularly and clinically similar to glio-
blastoma [40]. The detailed information of these molecular markers
above and their clinical relevance are listed in Table 1.
Disease management
General recommendations
Management of gliomas requires a multidisciplinary approach
and involves neuroimaging, surgery, neuropathology, radiation
therapy (RT), chemotherapy and supportive care. Karnofsky per-
formance score, neurological function, and age need to be considered
in clinical decision making in neuro-oncology.
Neuroimaging enables the noninvasive evaluation of glioma and
is considered to be one of the key factors for individualized therapy
and patient management, since accurate diagnosis and demarca-
tion of viable tumor tissue is required for treatment planning as well
as assessment of treatment response [45]. Computed tomography
(CT) scanning can demonstrate the tumor and associated ﬁnd-
ings; however, in making the glioma diagnosis, CT scanning is not
sensitive enough and may cause small tumors to be missed. Mag-
netic resonance imaging (MRI) is signiﬁcantly more sensitive to the
presence of tumor, as well as its proportion and location, which will
help guide diagnostic interventions such as biopsy and treatment
including surgery and radiation [46,47]. Positron emission tomog-
raphy (PET) scanning is also a useful supporting method in the
evaluation of gliomas, particularly for differential diagnosis. PET scan-
ning with 18-ﬂuorodeoxyglucose (FDG) is positive in cases of active
tumor, which shows high metabolic activity and glucose utiliza-
tion [48].
Surgical resection remains essential to the management of
gliomas across all grades. Maximal safe resection should be at-
tempted to protect patients’ neurological functions [49]. Gross total
resection is proposed as the result of its association with better clin-
ical outcome [50]. Meanwhile, many tools are available to increase
the extent of resection, while keeping the risk of new neurologi-
cal deﬁcits at a low level, including surgical navigation systems
housing functional MRI datasets, intraoperative MRI, and intraop-
erative functional monitoring [51]. However, it is also recommended
that biopsy, or partial resection, may all be considered as the initial
management of gliomas depending on the condition of the patient,
the size and location of the tumor, and so on [52]. Awake surgery
may help neurosurgeon to remove tumors which are too close to
the functional brain areas that control vision, language and body
movements [53]. Furthermore, surgical resection could improve
tumor related seizure control, particularly in patients with a long
epileptic history [54,55].
A suﬃcient amount of tumor tissue should be obtained for his-
tology and molecular analyses through resection or biopsy. The
inclusion of molecular parameters in the WHO deﬁnition of brain
tumors has been forwarded as the “ISN-Haarlem” consensus [56].
The “integrated” diagnosis was recommended based on histology
and stepwise analysis with initial immunohistochemistry for ATRX
and IDH1-R132H followed by 1p/19q status analysis and IDH1 and
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Table 1
Molecular biomarkers and their clinical relevance in gliomas.
Clinical
importance
IDH1/2
mutation
1p/19q
codeletion
MGMT promoter
methylation
EGFR vIII ATRX loss or
mutation
TERT promoter
mutation
miR-181d Ki-67
Methods of assessment IHC;
pyrosequencing
FISH MSP; bisulﬁte
(pyro) sequencing
rtPCR; IHC; MLPA IHC; Sanger
sequencing
Sanger sequencing qPCR, ISH IHC
Frequency (%) Diffuse
astrocytoma
70–80 15 40–50 0 70 18 NA 5
Oligoastrocytoma 50–70 30–60 60–80 0 50–60 31 NA 5
Oligodendroglioma 70–80 30–60 60–80 0 14 68–79 NA 5
Anaplastic
astrocytoma
50–70 15 50 0 60–80 18 NA 35–48
Anaplastic
oligoastrocytoma
50–70 50–80 70 0 70–80 31 NA 35–48
Anaplastic
oligodendrogliomas
50–80 50–80 70 0 7 68–79 NA 35–48
Glioblastoma Pri:5–10; Sec:57 <5 35 25–30 Pri:4; Sec:57 50–74 50 64
Biological role Increased
concentrations of
2-hydroxyglutarate,
association with
G-CIMP phenotype
Unclear, link to
candidate genes
CIC and FUBP1
Silencing DNA
damage repair,
association with
G-CIMP + in
IDH1/2-mutated
tumors
Constitutive
activation of
downstream
pro-oncogenic
pathways
Telomere
dysfunction,
genomic
destabilization
Overexpression of
TERT, maintain
telomerase activity
Downregulate
MGMT, K-ras, and
Bcl-2 expression
A nuclear protein
expressed during
the G1, S, G2 and M
phases of the cell
cycle, used as a
stable marker of
cell proliferation
Diagnostic role Differential
diagnosis between
diffuse glioma and
gliosis
Oligodendroglial
lineage
None Association with
glioblastoma
Astrocytic lineage Association with
primary
glioblastoma or
oligodendroglial
lineage
None None
Prognostic role Favorable survival
in IDH-mutated
tumors
Favorable survival
in 1p/19q
codeletion tumors
Favorable survival
in high grade
astrocytic tumors
Unfavorable
survival
Favorable survival
in astrocytic
tumors
Contradictory Favorable survival
in glioblastoma
Unfavorable
survival
Predictive role Absence of
mutation suggests
predictive role for
MGMT promoter
methylation
Patients for
(anaplastic)
oligodendrogliomas
treated with early
alkylating agents
Predictive for
glioblastoma
(elderly patients,
without IDH
mutation) treated
with alkylating
agents
Possible biomarker
for vaccination
None Potential
biomarker for
targeted therapy
Predictive for
glioblastoma
treated with
alkylating agents
None
Abbreviations: IHC, immunohistochemistry; FISH, ﬂuorescence in-situ hybridization; MSP, methylation-speciﬁc PCR; rtPCR, real-time PCR; MLPA, multiplex litigation-dependent probe ampliﬁcation; Pri, primary; Sec,
secondary. Table revised from refs [58], [78].
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IDH2 sequencing (Fig. 1) [57]. Post-operative radiation therapy and
chemotherapy should depend on the patients’ clinical informa-
tion, extent of resection, histology classiﬁcation and molecular
characteristics, and so on (Fig. 2). The assessment of IDH muta-
tion, 1p and 19q codeletion, andMGMT promoter methylation status
could be considered to establish a management algorithm for pa-
tients with anaplastic glioma and glioblastoma [58]. Additionally,
the decision for speciﬁc treatmentsmust consider several issues such
as patient preference, tumor location, target volume of radiother-
apy, and potential comorbidities that might increase the risk of
toxicity from therapy.
Low grade gliomas (WHO II, LGG)
Although recent advances have been made in chemotherapy and
radiation therapy for LGGs, surgical resection remains essential to
its management. A growing body of literature supports the claim
that a greater extent of resection leads to a signiﬁcant survival beneﬁt
for LGGs [59–65]. The National Comprehensive Cancer Network
(NCCN) guidelines for the management of low-grade inﬁltrative su-
pratentorial astrocytoma/oligodendroglioma in adult patients
recommend maximum safe resection of tumor tissue, if possible,
with the caveat that serial observation may be appropriate for se-
lected patients [66]. Observation may be reasonable in low-risk LGG
patients (≤40 years old and receiving gross total resection) [67] with
minimal or no symptoms [68], receiving MRI every 3–6 months for
5 years and then least annually. However, even in the low-risk cohort,
patients with astrocytoma histology were found to have had in-
creased rate of recurrence and death. Patients receiving early
radiotherapy may have a statistically signiﬁcant improvement in
progression-free survival, although overall survival is usually equiv-
alent. A total RT dose of 50.4–54 Gy in fractions of 1.8 Gy represents
the current standard of radiotherapy for LGGs [69,70]. Seizures are
also more likely to be controlled in the early radiotherapy group
[71]. According to several randomized clinical trials (RTOG 9802,
EORTC 22033 and RTOG 0424), patients with high-risk LGGs (>40
years old or none receiving gross total resection) could beneﬁt from
radiotherapy plus concurrent and adjuvant chemotherapy (or only
adjuvant chemotherapy) [72–75]. Although temozolomide has been
proved to be more tolerable than procarbazine, lomustine (CCNU),
and vincristine (PCV regimen), which justiﬁed the use of
temozolomide in the early setting as an alternative to PCV [74], the
ATRX Loss
O II/O III
IDH1 R132H /ATRX-IHC
Abbreviations: IHC, immunohistochemistry; mut, mutation; seq, sequencing; wt, wild type; O, oligodendroglioma; A, astrocytoma; GBM, glioblastoma. 
IDH1 R132H Positive
ATRX Positive
IDH1 R132H Positive IDH1 R132H Negative
ATRX Positive
IDH1 R132H Negative
ATRX Loss
1p/19q-assay 1p/19q-assay
IDH1/IDH2-seq
Codeletion None-codeletion Codeletion None-codeletion
IDH mut IDH wt
A II/A III/GBM
IDH mut O II/O III
A II/A III/GBM
IDH mut
A II/A III/GBM
IDH wt
Fig. 1. Algorithm for the integrated diagnosis of astrocytomas, oligodendrogliomas and glioblastomas. Figure adapted from ref [57].
Glioblastoma
IDH1/2
Mutation Wild Type
Age > 65 
years
Age 65 
years
MGMT+ MGMT-
RT       
RT/TMZ TMZ
TMZ
or
Anaplastic glioma
1p/19q
Codeletion None-codeletion
RT PCV
or
RT TMZ
or
TMZ (or PCV)
or
IDH1/2
Mutation Wild Type
MGMT+MGMT-
RT TMZ
or
RT
or
TMZ
or
PCV
Low grade glioma
Age 40 years 
and GTR
Age > 40 years 
or None-GTR
RT PCV /TMZ
or 
Observe
or
RT
or
PCV/TMZ
Abbreviations: GTR, gross tumor resection; RT, radiotherapy; TMZ, temozolomide; PCV, procarbazine, lomustine , and vincristine. 
RT       
Fig. 2. Treatment approach for gliomas based on clinical and molecular information. Figure revised from refs [58], [66], [79].
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beneﬁts of TMZ should now be considered more carefully against
its potentially adverse effects of hypermutation on the basis of the
studies on paired gliomas with IDH mutations [76,77].
Anaplastic gliomas (WHO III, AG)
Anaplastic gliomas comprise three histological subtypes: ana-
plastic astrocytoma (AA), anaplastic oligodendroglioma (AO) and
anaplastic oligoastrocytoma (AOA). Surgery by removing tumormass
and improving mass-related symptoms also allows the potential for
functional improvement of the patients [55]. Standard therapy con-
sists of adjuvant radiotherapy up to a total dose of 60 Gy after surgery
[78]. Postoperative chemotherapy following initial surgery varies
according to the histological type, molecular subtype and the clin-
ical status of the patients. 1p/19q codeletion harbors the predictive
value for the beneﬁt from chemotherapy, in addition to character-
ize a prognostically more favorable subgroup of patients with
anaplastic oligodendroglial tumors. Patients with 1p/19q-codeleted
oligodendroglial tumors may beneﬁt from radiotherapy plus PCV
after surgery [79–81]. TMZ is widely considered as less toxic than
PCV [14,18,81,82], and no difference in response rate or survival was
identiﬁed [83]. The outcome of TMZ in anaplastic gliomas in several
ongoing clinical trials is expected. CODEL trial was designed to
address whether the addition of temozolomide to radiotherapy in-
creased the survival of patients with codeleted tumors and answer
the question whether progression-free survival of the combina-
tion of radiotherapy and temozolomide is not relevantly different
from the combination of radiotherapy and PCV. Another phase III
trial “CATNON” will show whether combined radiochemotherapy
with temozolomide (concomitant and/or as an adjuvant mainte-
nance treatment) is superior to radiotherapy alone [84]. In summary,
1p/19q codeleted AGs may have several therapeutic options varying
in evidence-based recommendations: RT and adjuvant PCV, RT and
adjuvant TMZ, RT plus concomitant and adjuvant TMZ, or chemo-
therapy only (TMZ or PCV) [79]. In a sub-study for anaplastic gliomas,
MGMT promoter methylation was a predictive marker for re-
sponse to alkylating chemotherapy in IDH wild-type tumors only
and not in IDH mutated tumors [20,85]. On the other hand, pa-
tients with noncodeleted and nonmutated AO/AOA experienced no
discernible beneﬁt from the addition of PCV to RT. Combined
radiochemotherapy has not been established as superior to RT only
or chemotherapy only in newly diagnosed non-codeleted AGs
[66,84,86,87]. The NCCN recommends treatment of newly diag-
nosed AAs by RT only followed by observation and chemotherapy
at progression [66]. A retrospective study depicted that in pa-
tients with 1p/19q noncodeleted tumors with IDH mutations, those
whowere ATRX positivemight have beneﬁttedmore than those who
were negative from pre-RT PCV [88].
Glioblastoma (WHO IV, GBM)
The trial-EORTC 26981/NCIC CE3 was the ﬁrst study to demon-
strate unequivocally that addition of temozolomide to radiotherapy
for the treatment of patients with newly diagnosed glioblastoma
signiﬁcantly improved survival. Radiotherapy plus concomitant and
adjuvant TMZ chemotherapy is the current standard of care for pa-
tients less than 70 years old with GBM [18,89]. Radiation therapy,
usually dosed as 60 Gy in 30 fractions, has been the cornerstone of
glioblastoma therapy for decades [90]. The radiotherapy volume often
contains the T1-enhanced region plus a 2–3 cm safety margin on
the T2 or FLAIR abnormality [91]. TMZ is administered at 75mg/m2
daily (7 days a week) during radiotherapy and for six mainte-
nance cycles on 5 out of 28 days at 150–200mg/m2 as maintenance
(adjuvant) treatment after the end of radiation. Several clinical trials
and cohort studies have shown that MGMT promoter methylation
is associated with prolonged progression-free and overall survival
in patients with glioblastoma receiving alkylating drug chemother-
apy [19,89,92–95]. In 2012, two independent randomized trials in
elderly patients with glioblastoma assessed radiotherapy alone versus
temozolomide chemotherapy alone as initial treatment. Both
temozolomide and hypofractionated radiotherapy should be con-
sidered as standard treatment options in elderly patients with
glioblastoma. Subgroup analyses of both trials showed better
outcome for chemotherapy in patients with MGMT promoter meth-
ylated tumors, but reduced survival in patients with unmethylated
tumors [96,97]. On the basis of ﬁndings from the NOA-08 and Nordic
trials, MGMT testing should be standard practice [21]. Recently, the
CGGA project reported that patients with IDH wild-type glioblas-
tomawho underwent RT + TMZ exhibited signiﬁcantly longer survival
times compared to the patients who were assigned to the RT alone
treatment. However, among patients with IDHmutation tumors, the
survival patterns of patients undergoing RT + TMZ or RT were com-
parable [98]. IDH mutations have been recognized as deﬁnitive
diagnostic molecular markers of secondary glioblastoma, distinc-
tive from de novo glioblastoma andmore reliable and objective than
clinical and/or pathological criteria [33]. These results strongly
suggest that treatment strategies for elderly patients with glioblas-
toma should be individualized dependent on IDH and MGMT [58].
Two large-scale randomized trials have showed that patients with
newly diagnosed glioblastoma, when receiving bevacizumab in ad-
dition to temozolomide chemoradiotherapy, could beneﬁt in
progression-free survival, but not in overall survival [99,100].
Tumor recurrence
Standards of care for patients with recurrent glioma are not well
deﬁned and clinical decisionmaking is often based on histology clas-
siﬁcation, previous treatment, age, Karnofsky performance score,
molecular information and patterns of relapse. At tumor progres-
sion, second surgery becomes the potential option, which should
typically be considered when patients have large but circum-
scribed lesions causing neurological deﬁcits and when the interval
between surgeries is more than 6 months. However, there are no
prospective data available on the impact of repeat surgery on OS.
Retrospective analyses also failed to identify surgery for recurrent
disease as a signiﬁcant prognostic factor for prolonged survival
[101,102]. For recurrent patients who have already received radi-
ation, hypofractionated radiotherapy (e.g., with 25–30 Gy in ﬁve
fractions of 5 or 6 Gy, or with 35 Gy in ten 3·5 Gy fractions) is fea-
sible if relapses are circumscribed and chemotherapy is
contraindicated. Alkylating agent chemotherapy is the treatment of
choice for most tumors previously untreated with chemotherapy
that relapse after receiving radiotherapy. In NCCN guidelines, the
antiangiogenic therapy with bevacizumab is also recommended in
the management of progressive malignant gliomas. Although pa-
tients cannot get overall survival beneﬁt from bevacizumab
[103–105], bevacizumab is universally accepted because of evident
symptom relief effects, for example, reducing cerebral edema [106].
Randomized trials in recurrent glioblastoma have failed to dem-
onstrate the signiﬁcant anti-tumor eﬃcacy of epidermal growth
factor receptor (EGFR) inhibition (e.g. erlotinib) or platelet-derived
growth factor receptor inhibition (e.g. imatinib) [107,108].
Supportive care
Corticosteroids (usually dexamethasone 8–16mg/day) are often
prescribed to patients for control of tumor-associated edema and
improving clinical symptoms. Steroids are not necessary in pa-
tients without increased intracranial pressure or in the absence of
edema-associated neurological deﬁcits. There is no need for pro-
longed steroid therapy after tumor resection or for prophylaxis during
radiotherapy in asymptomatic patients. Rapid tapering and
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discontinuation of corticosteroids is recommended in order to avoid
toxicity associated with prolonged exposure to steroids, e.g. lym-
phopenia and risk of infection, osteoporosis and Cushing syndrome.
Anti-epileptic therapy is indicated in patients presenting with
seizures. If no further seizure occurs after surgery and the tumor
seems to be controlled by treatment, tapering of anticonvulsants
should be attempted within the ﬁrst weeks or months after surgery.
After tumor resection, the indication for anti-epileptic therapy should
be revisited only if seizures occur [109,110].
Patients with gliomas are at increased risk of thromboembolic
events throughout the course of disease due to many reasons, in-
cluding neurological deﬁcits, steroid use, radiotherapy, chemotherapy,
and release of vasoactive molecules from glioma cells [111]. Pro-
phylactic anticoagulation is not recommended; however, a low
threshold for excluding deep vein thrombosis and pulmonary emboli
is indicated when suspicious symptoms occur.
Response evaluation and follow-up
The Response Assessment in Neuro-Oncology (RANO) deﬁnes a
set of criteria for assessing outcome in trials of adult gliomas
[112,113], including speciﬁc guidelines for using tumor size and ap-
pearance on T2/FLAIR MRI sequences to deﬁne tumor response. The
criteria take into account stability of corticosteroid dosing, neuro-
logical function, clinical status (Macdonald criteria) [114], and
differentiation between new T2 or FLAIR abnormalities related to
tumor spread in comparison with those attributable to radiation
effects. MRI should be utilized to evaluate the eﬃcacy of treat-
ment or as surveillance imaging after completion of treatment at
an interval of 3–6 months. Contrast enhancement and presumed
tumor progression on imaging 4–8 weeks after the end of
radiotherapy may be a reactive process following radiotherapy
(pseudo-progression) [115] and should be re-evaluated 4weeks later
with a second MRI. Longer intervals might be considered for pa-
tients with lengthy disease control, notably young patients with 1p/
19q-codeleted oligodendroglial tumors. Laboratory tests should also
be indicated if the patient is receiving chemotherapy (blood counts),
corticosteroids (glucose) or anti-epileptic drugs (blood count, liver
function tests).
Note
The following electronic databases were searched: the Co-
chrane Library to date; Medline–Ovid (January 1966 to date);
Medline–ProQuest; Medline-EIFL; Embase–Ovid (January 1990 to
date); CancerNet; and Science Citation Index. We used speciﬁc and
sensitive keywords, as well as combinations of keywords, and pub-
lications in any language of countries represented in the Task Force.
The search was completed in June 2015.
The Panel covered all ﬁelds of expertise in neuro-oncology, i.e.
neurosurgeons, neurologists, neuropathologists, neuroradiologists,
radiation and medical oncologists and clinical trial experts. The sci-
entiﬁc evidence of papers collected from the literature was evaluated
and graded and recommendations were given accordingly. These
are summarized in Table 2 with explanatory notes, and state-
ments without grading were considered justiﬁed standard clinical
practice by the expert authors and the CGCG faculty. The Oxford
Centre for Evidence-based Medicine Levels of Evidence and Grades
of Recommendation (March 2009) are shown in Table 3 and Table 4
[116].
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Table 2
Conclusion and recommendations.
Level of
evidence
Grade of
recommendation
General recommendations
Gliomas are diagnosed using morphological criteria according to WHO classiﬁcation. 1a A
Karnofsky performance score, neurological function, and age need to be considered in clinical decision making in neuro-oncology. 1b A
Magnetic resonance imaging (MRI) can be used to detect the presence of tumor and guide managements such as biopsy, surgery and
radiation.
2b B
Maximal safe resection is the ﬁrst option for all gliomas, while minimizing the postoperative morbidity. 2a B
When surgery is not feasible, a biopsy should be performed to obtain a histological diagnosis. 4 C
MGMT promoter methylation, IDH mutations and 1p/19q codeletion are commonly determined depending on the histological and
clinical contexts.
1b A
Low grade gliomas (WHO grade II)
Younger patients (≤40 years of age) with gross total resection can be observed after surgery, but close follow-up is needed. 1b B
For patients with high risk (age >40 years or none receiving gross total resection), an adjuvant treatment is indicated at any time. 1b B
Radiotherapy may be selected for high risk patients (age >40 years or gross total resection not received). 1b A
Chemotherapy is an option as initial treatment for patients with large residual tumors after surgery or unresectable tumors, especially
when 1p/19q loss is present.
1b B
Anaplastic gliomas (WHO grade III)
Patients with 1p/19q co-deleted anaplastic oligodendroglioma (oligoastrocytoma) should receive chemotherapy with alkylating agents
with or without radiotherapy.
1b B
MGMT promoter methylation could be a predictive marker for response to alkylating chemotherapy in IDH wild-type anaplastic gliomas. 2b B
Temozolomide chemotherapy is standard treatment at progression after surgery and radiotherapy. 1b A
Glioblastoma (WHO grade IV)
Radiotherapy combined with temozolomide remains the standard of care for newly diagnosed glioblastoma. 1b A
In elderly patients (>65 years) with IDH wild-type and MGMT promoter methylation, temozolomide chemotherapy may be considered,
while radiotherapy is the treatment of choice for patients with an unmethylated gene promoter.
1b B
Bevacizumab (±irinotecan) is an option for the management of recurrent glioblastoma. 1b B
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Table 3
Levels of evidence.
Level Therapy/Prevention, etiology/Harm Prognosis Diagnosis
1a SR (with homogeneity*) of RCTs SR (with homogeneity*) of inception cohort
studies; CDR† validated in different populations
SR (with homogeneity*) of level 1 diagnostic
studies; CDR† with 1b studies from different
clinical centers
1b Individual RCT (with narrow conﬁdence interval) Individual inception cohort study with >80%
follow-up; CDR† validated in a single population
Validating** cohort study with good††† reference
standards; or CDR† tested within one clinical
center
1c All or none§ All or none case-series Absolute SpPins and SnNouts††
2a SR (with homogeneity*) of cohort studies SR (with homogeneity*) of either retrospective
cohort studies or untreated control groups in RCTs
SR (with homogeneity*) of level >2 diagnostic
studies
2b Individual cohort study (including low quality RCT;
e.g., <80% follow-up)
Retrospective cohort study or follow-up of
untreated control patients in an RCT; derivation of
CDR† or validated on split-sample§§§ only
Exploratory** cohort study with good††† reference
standards; CDR† after derivation, or validated only
on split-sample§§§ or databases
2c “Outcomes” research; ecological studies “Outcomes” Research
3a SR (with homogeneity*) of case–control studies SR (with homogeneity*) of 3b and better studies
3b Individual case–control study Non-consecutive study; or without consistently
applied reference standards
4 Case-series (and poor quality cohort and
case–control studies§§)
Case-series (and poor quality prognostic cohort
studies***)
Case–control study, poor or non-independent
reference standard
5 Expert opinion without explicit critical appraisal,
or based on physiology, bench research or “ﬁrst
principles”
Expert opinion without explicit critical appraisal,
or based on physiology, bench research or “ﬁrst
principles”
Expert opinion without explicit critical appraisal,
or based on physiology, bench research or “ﬁrst
principles”
* Homogeneity means a systematic review (SR) that is free of worrisome variations (heterogeneity) in the directions and degrees of results between individual studies.
Not all SRs with statistically signiﬁcant heterogeneity need be worrisome, and not all worrisome heterogeneities need be statistically signiﬁcant.
† Clinical decision rule. (Algorithms or scoring systems which lead to a prognostic estimation or a diagnostic category.)
§ Met when all patients died before the treatment became available, but some now survive on it; or when some patients died before the treatment became available, but
none now die on it.
§§ Poor quality cohort study: one that failed to clearly deﬁne comparison groups and/or failed to measure exposures and outcomes in the same (preferably blinded) ob-
jective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known confounders and/or failed to carry out a suﬃciently long
and complete follow up of patients. Poor quality case–control study: one that failed to clearly deﬁne comparison groups and/or failed to measure exposures and outcomes
in the same (preferably blinded) objective way in both cases and controls and/or failed to identify or appropriately control known confounders.
§§§ Split sample validation is achieved by collecting all the information in a single tranche, then artiﬁcially dividing this into “derivation” and “validation” samples.
†† An “Absolute SpPin”: a diagnostic ﬁnding whose speciﬁcity is so high that a positive result rules in the diagnosis. An “Absolute SnNout”: a diagnostic ﬁnding whose
sensitivity is so high that a negative result rules out the diagnosis.
††† Good reference standards are independent of the test, and applied blindly or objectively to all patients. Poor reference standards are haphazardly applied, but still in-
dependent of the test. Use of a non-independent reference standard (where the “test” is included in the “reference”, or where the “testing” affects the “reference”) implies
a level 4 study.
** Validating studies test the quality of a speciﬁc diagnostic test, based on prior evidence. An exploratory study collects information and trawls the data (for example,
using a regression analysis) to ﬁnd which factors are “signiﬁcant.”
*** Poor quality prognostic cohort study: one in which sampling was biased in favor of patients who already had the target outcome, or the measurement of outcomes was
accomplished in <80% of study patients, or outcomes were determined in an unblinded, non-objective way, or there was no correction for confounding factors. Table adapted
from ref [116].
Table 4
Grades of recommendation.
Grades Description
A Consistent level 1 studies
B Consistent level 2 or 3 studies or extrapolations from level 1
studies
C Level 4 studies or extrapolations from level 2 or 3 studies
D Level 5 evidence or troublingly inconsistent or inconclusive
studies of any level
Table adapted from ref [116].
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